Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Zurich
About this trial
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.
The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female and Male, age ≥18 years at screening.
Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
Ability to understand the requirements of the study and to provide informed consent.
Willingness to undergo follow-up.
Disqualifiers
Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).
Autoimmune or systemic inflammatory diseases.
Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases).
Age<18 years old
Trial population
The study aims to enroll all patients presenting with clinical signs and symptoms of acute heart failure. As this is an all-comer cohort, the investigators expect no selection bias in terms of sex and gender.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 3 trial groupsGroup A: Heart Failure with reduced ejection fraction (HFrEF)
Group B: Heart Failure with preserved ejection fraction (HFpEF)
Group C: Heart Failure with mildyly reduced ejection fraction (HFmrEF)
Trial outcomes
Primary outcomes
1
Death from any cause
Time frame
From enrollment up to five years2
Heart failure hospitalization
Time frame
From enrollment up to five yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov